Loading...
The search for effective nucleoside-sparing antiretroviral regimens continues. In the latest study in this effort, investigators randomized 121 treatment-naive HIV-infected patients with CCR5-tropic virus to receive ritonavir-boosted atazanavir with either maraviroc or tenofovir/FTC. The study was sponsored by the maker of maraviroc and was presented at the 6th IAS Conference on HIV Pathogenesis, Treatment and Prevention [Portsmouth S et al. Abstract TUAB0103].
After 48 weeks of treatment, 75% of patients in the maraviroc group and 84% of those in the tenofovir/FTC group had viral loads <50 copies/mL. This difference was not statistically significant but was apparent both in patients with baseline viral loads ≥100,000 copies/mL and in those …